Rabson-Mendenhall syndrome is a rare genetic disorder resulting from mutations in the insulin receptor and is associated with high degrees of insulin resistance. These patients are prone to complications secondary to their hyperglycemia including diabetic ketoacidosis (DKA). We report the case of a 19-year-old male with Rabson-Mendenhall syndrome presenting with DKA who required doses of up to 500 U/h (10.6 U/kg/h) of insulin. The patient’s insulin infusion was originally compounded with U-100 regular insulin, although to minimize volume, the product was compounded with U-500 insulin. The DKA eventually resolved requiring infusion rates ranging from 400 to 500 U/h. Although numerous opportunities for medication errors exist with the use of U-500 insulin, this case outlines the safe use of concentrated intravenous insulin when clinically indicated for patients requiring extremely high doses of insulin to control blood glucose.
HassanIAltafHYaseenA. Rabson-Mendenhall syndrome. Indian J Dermatol. 2014;59(6):633.
6.
Paz-FilhoGMastronardiCALicinioJ. Leptin treatment: facts and expectations. Metabolism. 2015;64(1):146–156.
7.
BrownRJCochranEGordenP. Metreleptin improves blood glucose in patients with insulin receptor mutations. J Clin Endocrinol Metab. 2013;98(11):E1749–E1756.
8.
ChongYHTaylorBJWheelerBJ. Renal manifestations of severe Rabson-Mendenhall syndrome: a case report. J Diabetes Metab Disord. 2013;12(1):7.
9.
DuttaDMaisnamIGhoshS. Syndrome of extreme insulin resistance (Rabson-Mendenhall phenotype) with atrial septal defect: clinical presentation and treatment outcomes. J Clin Res Pediatr Endocrinol. 2013;5(1):58–61.
10.
MohananSChandrashekarLSempleRK. Rabson-Mendenhall syndrome with recurrent cerebral infarcts caused by a novel INSR mutation. Int J Dermatol. 2013;52(2):182–185.
11.
GuptaJDanielJMVasudevanV. Rabson-Mendenhall syndrome. J Indian Soc Pedod Prev Dent. 2012;30(3):279–282.
12.
JiangSFangQZhangF. Functional characterization of insulin receptor gene mutations contributing to Rabson-Mendenhall syndrome—phenotypic heterogeneity of insulin receptor gene mutations. Endocr J. 2011;58(11):931–940.
13.
MoreiraROZaguryRLNascimentoTS. Multidrug therapy in a patient with Rabson-Mendenhall syndrome. Diabetologia. 2010;53(11):2454–2455.
14.
Carrasco de la FuenteMBarrio CastellanosRAlonso BlancoM. Long survival in Rabson-Mendenhall syndrome. Diabetes Res Clin Pract. 2010;89(2): e17–e18.
MussoCCochranEMoranSA. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83(4):209–222.
17.
CochranEYoungJRSebringN. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab. 2004;89(4):1548–1554.
18.
LongoNSinghRElsasLJ. Decreased half-life of insulin-like growth factor I in Rabson-Mendenhall syndrome. J Inherit Metab Dis. 2001;24(5):546–550.
19.
SimpkinACochranECameronF. Insulin receptor and the kidney: nephrocalcinosis in patients with recessive INSR mutations. Nephron Physiol. 2014;128:55–61.
20.
GrassoVColomboCFavalliV. Six cases with severe insulin resistance (SIR) associated with mutations of insulin receptor: is a Bartter-like syndrome a feature of congenital SIR?Acta Diabetol. 2013;50(6):951–957.
21.
KimDChoSYYeauSH. Two novel insulin receptor gene mutations in a patient with Rabson-Mendenhall syndrome: the first Korean case confirmed by biochemical, and molecular evidence. J Korean Med Sci. 2012;27(5):565–568.
22.
ThielCTKnebelBKnerrI. Two novel mutations in the insulin binding subunit of the insulin receptor gene without insulin binding impairment in a patient with Rabson-Mendenhall syndrome. Mol Genet Metab. 2008;94(3):356–362.
23.
TuthillASempleRKDayR. Functional characterization of a novel insulin receptor mutation contributing to Rabson-Mendenhall syndrome. Clin Endocrinol (Oxf). 2007;66(1):21–26.
24.
CotugnoGPollockRFormisanoP. Pharmacological regulation of the insulin receptor signaling pathway mimics insulin action in cells transduced with viral vectors. Hum Gene Ther. 2004;15(11):1101–1108.
25.
DavisAYarasheskiKEWhiteNH. Defective insulin receptors in Rabson-Mendenhall syndrome cause complete peripheral insulin resistance but minimal hepatic insulin response remains. Pediatr Diabetes. 2000;1(2):66–73.
26.
MaassenJATobiasESKayserilliH. Identification and functional assessment of novel and known insulin receptor mutations in five patients with syndromes of severe insulin resistance. J Clin Endocrinol Metab. 2003;88(9):4251–4257.
27.
LongoNWangYSmithSA. Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet. 2002;11(12):1465–1475.
28.
KadowakiHTakahashiYAndoA. Four mutant alleles of the insulin receptor gene associated with genetic syndromes of extreme insulin resistance. Biochem Biophys Res Commun. 1997;237(3):516–520.
29.
KrookASoosMAKumarS. Functional activation of mutant human insulin receptor by monoclonal antibody. Lancet. 1996;347(9015):1586–1590.
30.
KrookAO’RahillyS. Mutant insulin receptors in syndromes of insulin resistance. Baillieres Clin Endocrinol Metab. 1996;10(1):97–122.
31.
KrookAKumarSLaingI. Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes. 1994;43(3):357–368.
32.
Muller-WielandDvan der VormERStreicherR. An in-frame insertion in exon 3 and a nonsense mutation in exon 2 of the insulin receptor gene associated with severe insulin resistance in a patient with Rabson-Mendenhall syndrome. Diabetologia. 1993;36(11):1168–1174.
33.
KadowakiTKadowakiHRechlerMM. Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. J Clin Invest. 1990;86(1):254–264.
34.
MoncadaVYHedoJASerrano-RiosM. Insulin-receptor biosynthesis in cultured lymphocytes from an insulin-resistant patient (Rabson-Mendenhall syndrome). Evidence for defect before insertion of receptor into plasma membrane. Diabetes. 1986;35(7):802–807.
35.
MaronRTaylorSIJacksonR. Analysis of insulin receptors on human lymphoblastoid cell lines by flow cytometry. Diabetologia. 1984;27 suppl:118–120.
36.
TaylorSIUnderhillLHHedoJA. Decreased insulin binding to cultured cells from a patient with the Rabson-Mendenhall syndrome: dichotomy between studies with cultured lymphocytes and cultured fibroblasts. J Clin Endocrinol Metab. 1983;56(4):856–861.
37.
RabboneIGalderisiATintiD. Case report: when an induced illness looks like a rare disease. Pediatrics. 2015;136(5):e1361–e1365.
38.
BathiRJParveenSMutalikS. Rabson-Mendenhall syndrome: case reports and a brief review of the literature. Odontology. 2010;98(1):89–96.
HarrisAMHallBKrissVM. Rabson-Mendenhall syndrome: medullary sponge kidney, a new component. Pediatr Nephrol. 2007;22(12):2141–2144.
41.
MussoCShawkerTCochranE. Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth. Clin Endocrinol (Oxf). 2005;63(1):73–78.
42.
KumarSTulluMSMuranjanMN. Rabson-Mendenhall syndrome. Indian J Med Sci. 2005;59(2):70–73.
43.
HardawayCAGibbsNF. What syndrome is this? Rabson-Mendenhall syndrome. Pediatr Dermatol. 2002;19(3):267–270.
44.
LongoNWangYPasqualiM. Progressive decline in insulin levels in Rabson-Mendenhall syndrome. J Clin Endocrinol Metab. 1999;84(8):2623–2629.
45.
Desbois-MouthonCMagreJDupreyJ. Major circadian variations of glucose homeostasis in a patient with Rabson-Mendenhall syndrome and primary insulin resistance due to a mutation (Cys284-->Tyr) in the insulin receptor alpha-subunit. Pediatr Res. 1997;42(1):72–77.
46.
LongoNSinghRGriffinLD. Impaired growth in Rabson-Mendenhall syndrome: lack of effect of growth hormone and insulin-like growth factor-I. J Clin Endocrinol Metab. 1994;79(3):799–805.
47.
TakataYKobayashiMMaegawaH. A primary defect in insulin receptor in a young male patient with insulin resistance. Metabolism. 1986;35(10):950–955.
48.
RabsonSMMendenhallEN. Familial hypertrophy of pineal body, hyperplasia of adrenal cortex and diabetes mellitus; report of 3 cases. Am J Clin Pathol. 1956;26(3):283–290.
49.
QuinnSLLansangMCMinaD. Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus. Pharmacotherapy. 2011;31(7):695–702.
50.
GargRJohnstonVMcNallyPG. U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev. 2007;23(4):265–268.
